BioCentury
ARTICLE | Company News

Arrowhead endocrine news

April 11, 2011 7:00 AM UTC

Arrowhead increased its stake in its Ablaris Therapeutics Inc. subsidiary to 64% from 55% after investing an additional $800,000 in the subsidiary in the second and final closing of a series A round. ...